Cardiff Oncology Insider Buying Signals Confidence Amid Volatile Valuation
Cardiff Oncology insider‑buying spurs investor curiosity: insider options, a 52‑week low, and a solid‑tumor ADC pipeline may signal upside if clinical milestones hit.
4 minutes to read